Assembly Biosciences Inc ((ASMB)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Assembly Biosciences Inc. is conducting a Phase 1a/1b clinical study titled A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-5366, a potential treatment for recurrent genital herpes caused by HSV-2. This research is significant as it explores a new therapeutic option for a condition that affects millions globally.
Intervention/Treatment: The study tests ABI-5366, an experimental drug administered as a tablet. It is designed to be taken either as a single ascending dose (SAD) or multiple ascending doses (MAD) to assess its effects on participants, including those with recurrent genital herpes.
Study Design: This interventional study is randomized with a parallel assignment model. It employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment assignments. The primary purpose is treatment-focused, aiming to determine the drug’s efficacy and safety.
Study Timeline: The study began on April 18, 2024, with the primary completion and estimated study completion dates yet to be announced. The latest update was submitted on July 23, 2025, indicating ongoing recruitment and progress.
Market Implications: This study update could influence Assembly Biosciences’ stock performance positively if the results show promise, as it would represent a significant advancement in HSV-2 treatment. Investors might view this as a competitive edge in the pharmaceutical industry, potentially affecting market dynamics and investor sentiment.
The study is ongoing, with further details available on the ClinicalTrials portal.